The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...
SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- On July 22, 2025, investors in Nutex Health Inc. (NASDAQ: NUTX) saw the price of their shares significantly fall after activist investment firm Blue Orca Capital published a critical report about Nutex and its involvement with independent dispute resolution (“IDR”) vendor HaloMD.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative
WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.
Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...
Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...